CAPR on Nasdaq
CAPRICOR THERAPEUTICS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with NextCure, Inc., NewAmsterdam Pharma Co N.V. or Prenetics Global Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $0 | $22.3M |
| TOTAL REVENUE | $0 | $22.3M |
| Research and development | $84.5M | $50.0M |
| General and administrative | $23.7M | $14.9M |
| TOTAL OPERATING EXPENSES | $108.1M | $64.8M |
| LOSS FROM OPERATIONS | -$108.1M | -$42.6M |
| Other income | $45.4K | $7.5K |
| Investment income | $6.3M | $2.2M |
| Interest expense | -$3.0M | $0 |
| Loss on disposal of fixed assets | -$157.5K | -$112.8K |
| TOTAL OTHER INCOME (EXPENSE) | $3.1M | $2.1M |
| LOSS BEFORE INCOME TAXES | -$105.0M | -$40.5M |
| (Provision for) benefit from income taxes | -$1.6K | -$1.6K |
| NET LOSS | -$105.0M | -$40.5M |
| Net unrealized gain (loss) on marketable securities | -$743.8K | $791.1K |
| COMPREHENSIVE LOSS | -$105.8M | -$39.7M |
| Net loss per share, basic (in dollars per share) | -$2.26 | -$1.15 |
| Net loss per share, diluted (in dollars per share) | -$2.26 | -$1.15 |
| Weighted average number of shares, basic (in shares) | 46.5M shares | 35.2M shares |
| Weighted average number of shares, diluted (in shares) | 46.5M shares | 35.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $287.8M | $11.3M | |
| Marketable securities | $30.3M | $140.2M | |
| Receivables | $59.2K | $10.4M | |
| Prepaid expenses and other current assets | $4.8M | $1.5M | |
| TOTAL CURRENT ASSETS | $322.9M | $163.4M | |
| PROPERTY AND EQUIPMENT, net | $18.3M | $5.6M | |
| Lease right-of-use assets, net | $13.5M | $1.3M | |
| Other assets | $1.2M | $221.7K | |
| TOTAL ASSETS | $355.9M | $170.5M | |
| Accounts payable | $1.7M | $3.3M | |
| Accrued expenses | $15.6M | $4.9M | |
| Lease liabilities, current | $202.4K | $834.8K | |
| CIRM liability, current | $6.4M | $0 | |
| Deferred revenue, current | $12.0M | $12.0M | |
| TOTAL CURRENT LIABILITIES | $35.8M | $21.0M | |
| CIRM liability, net of current | $0 | $3.4M | |
| Lease liabilities, net of current | $14.3M | $616.3K | |
| TOTAL LONG-TERM LIABILITIES | $14.3M | $4.0M | |
| TOTAL LIABILITIES | $50.2M | $25.0M | |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 57,370,909 and 45,582,288 shares issued and outstanding, respectively | $57.4K | $45.6K | |
| Additional paid-in capital | $610.3M | $344.2M | |
| Accumulated other comprehensive income | $283.2K | $1.0M | |
| Accumulated deficit | -$304.9M | -$199.8M | |
| TOTAL STOCKHOLDERS' EQUITY | $305.8M | $145.5M | $22.6M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $355.9M | $170.5M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common Stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 57.4M shares | 45.6M shares | |
| Common stock, shares outstanding | 57.4M shares | 45.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$105.0M | -$40.5M |
| Loss on disposal of fixed assets | $157.5K | $112.8K |
| Depreciation and amortization | $1.9M | $1.4M |
| Stock-based compensation | $17.0M | $9.8M |
| Restricted stock awards granted | $257.5K | $0 |
| Changes in lease liabilities | $715.5K | -$47.3K |
| Non-cash interest expense on CIRM liability | $3.0M | $0 |
| Receivables | $10.3M | $3.5K |
| Prepaid expenses and other assets | -$4.1M | -$458.7K |
| Accounts payable and accrued expenses | $6.0M | $1.9M |
| Deferred revenue | $0 | -$12.3M |
| Net cash used in operating activities | -$69.8M | -$40.0M |
| Purchase of marketable securities | -$151.4M | -$208.4M |
| Proceeds from sales and maturities of marketable securities | $260.6M | $93.8M |
| Purchases of property and equipment | -$2.9M | -$1.2M |
| Payments for leasehold improvements | -$383.5K | -$372.1K |
| Payments for construction in progress | -$8.4M | $0 |
| Net cash provided by (used in) investing activities | $97.5M | -$116.2M |
| Net proceeds from sale of common stock | $237.0M | $152.3M |
| Proceeds from exercise of stock awards and warrants | $11.9M | $450.2K |
| Net cash provided by financing activities | $248.9M | $152.8M |
| Net increase (decrease) in cash and cash equivalents | $276.6M | -$3.4M |
| Interest paid in cash | $0 | $0 |
| Income taxes paid in cash | $1.6K | $1.6K |
| Initial recognition of right-of-use asset | $13.4M | $0 |
Former names
Recent filings
- Oct 14, 2026SCHEDULE 13G/A
- Sep 14, 2026SCHEDULE 13G
- Aug 24, 20268-K
- Aug 19, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 202610-Q
- Aug 13, 20268-K
- Aug 7, 2026SCHEDULE 13G
- Aug 3, 2026SCHEDULE 13G
- Jul 30, 20268-K
- Jul 29, 20268-K
- Jul 14, 20268-K
- Jun 29, 20264
- Jun 29, 20264
- Jun 26, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10